A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors

Oncology

Volumn 71, Issue 3-4, 2007, Pages 197-203

  Kalykaki, A ^a   Vamvakas, L ^a   Agelaki, S ^a   Kalbakis, K ^a   Vardakis, N ^a   Sfakiotaki, G ^a   Ignatiadis, M ^a   Saridaki, Z ^a   Karabeazis, A ^a   Mavroudis, D ^a   Georgoulias, V ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Gemcitabine; Pemetrexed; Phase I trial; Solid tumor

Indexed keywords

AMINOTRANSFERASE; CISPLATIN; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; GEMCITABINE; HEMOPOIETIC GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; PACLITAXEL; PEMETREXED; SALICYLIC ACID;

ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY CARCINOMA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; MALIGNANT MESOTHELIOMA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; SOLID TUMOR; THERAPY DELAY; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; GLUTAMATES; GUANINE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

EID: 34548081192     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000106069     Document Type: Article

References (35)

1. Hanauske AR, Chen V, Paoletti P, Niyikiza C: Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001;6:363-373.
2. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM: LY231514, a pyrrolo(2,3-d)pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997;57:1116-1123.
3. Vogelzang NJ, Rusthoven JJ, Symanowski J Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-2344.
4. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn PA Jr: Randomized phase III trial of pemetrexed versus docetaxel in patients with nons-mall-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
5. Martin M, Spielmann M, Namer M, duBois A, Unger C, Dodwell D, Vodvarka P, Lind M, Calvert H, Casado A, Zelek L, Lluch A, Carrasco E, Kayitalire L, Zielinski C: Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann Oncol 2003;14:1246-1252.
6. Miller KD, Picus J, Blanke C John W, Clark J, Shulman LN, Thornton D, Rowinsky E, Loehrer PJ Sr: Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 2000;11:101-103.
7. Thodman R, Sauter T, Weinknecht S, Weissbach L, Blatter J, Ohnmacht U, Hanauske A: A phase II trial of pemetrexed in patients with metastatic renal cancer. Invest New Drugs 2003;21:353-358.
8. Goedhals L, van Wijk AL: MTA (LY231514) in advanced carcinoma of the cervix. Ann Oncol 1998;9(suppl 2):761.
9. Bajetta E, Celio L, Buzzoni R, Ferrari L, Marchianò A, Martinetti A, Longarini R, Becerra C, Ilardi C, John W: Phase II study of pemetrexed disodium (Alimta®) administered with oral folic acid in patients with advanced gastric cancer. Ann Onc 2003;14:1543-1548.
10. John W, Picus J, Blanke CD, Clark JW, Schulman LN, Rowinsky EK, Thornton DE, Loehrer PJ: Multitargeted antifolate (pemetrexed disodium, LY231514) activity in patients with advanced colorectal cancer: results from a phase II study. Cancer 2000;88:1807-1813.
11. Cripps C, Burnell M, Jolivet J, et al: Phase II study of first-line LY231514 (multitargeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC clinical trials group study. Ann Oncol 1999;10:1175-1179.
12. Pivot X, Raymond E, Laguerre B Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M: Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 2001;85:649-655.
13. von der Maase H: Pemetrexed in transitional cell carcinoma of the urothelium. Oncology (Williston Park) 2004;18(suppl 8):48-50.
14. Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckardt JR, Rodriguez G, Corso SW, Fields SM, Langley C: Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995;13:2842-2850.
15. McDonald AC, Vasey PA, Adams L: A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 1998;4:605-629.
16. Niyikiza C, Baker SD, Seitz DE, Walling JM, Nelson K, Rusthoven JJ, Stabler SP, Paoletti P, Calvert AH, Allen RH: Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-552.
17. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V: Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995;22(suppl 11):3-10.
18. Green M: Gemcitabine safety overview. Semin Oncol 1996;23(suppl 10):32-35.
19. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, Danesi R: Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small cell lung cancer cells. Mol Pharmacol 2005;68:110-118.
20. Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG: Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999;59:3671-3676.
21. Adjei AA, Erlichman C, Sloan JA, Reid JM, Pitot HC, Goldberg RM, Peethambaram P, Atherton P, Hanson LJ, Alberts SR, Jett J: Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors. J Clin Oncol 2000;18:1748-1757.
22. Dy GK, Suri A, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Atherton PJ, Hanson LJ, Burch PA, Rubin J, Erlichman C, Adjei AA: A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. Cancer Chemother Pharmacol 2005;55:522-530.
23. Monnerat C, Le Chevalier T, Kelly K, Obasaju CK, Brahmer J, Novello S, Nakamura T, Liepa AM, Bozec L, Bunn PA Jr, Ettinger DS: Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 2004;10:5439-5446.
24. Ma CX, Steen P, Rowland KM, Niedringhaus RD, Kugler JW, Ingle JN, Perez EA, Adjei AA: A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): an NCCTG study (abstract 639). Proc Am Soc Clin Oncol 2004;23:36.
25. Treat J, McCleod M, Mintzer D, Christiansen N, Bonomi P, Monberg M, Taylor L, Obasaju C: Pemetrexed plus gemcitabine as front-line therapy for patients with advanced stage non-small cell lung cancer (abstract 7130). Proc Am Soc Clin Oncol 2004;22:648s.
26. National Cancer Institute: Guidelines for Reporting Adverse Drug Reactions, Division of Cancer Treatment. Bethesda, National Cancer Institute, 1978.
27. World Health Organization: Handbook for Reporting Results of Cancer Treatment (WHO Offset Publication No. 48). Geneva, World Health Organization, 1979.
28. Adjei AA: Clinical studies of pemetrexed and gemcitabine combinations. Ann Oncol 2006;17(suppl 5):v29-v32.
29. Monnerat C, Le Chevalier T: Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer. Ann Oncol 2006;17(suppl 5):v86-v90.
30. Ma CX, Nair S, Thomas S, Manddrekar SJ, Nikcevich DA, Rowland KM, Fitch TR, et al: Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5929-5937.
31. Melemed AS, Larson T, Dudek AZ, Mellskog E, Bloss LP, Ye Z, Obasaju CK: Final report of a phase I clinical study of biweekly pemetrexed and gemcitabine in patients with advanced solid tumors: second dosing schedule and response (abstract 7257). Proc Am Soc Clin Oncol 2005;23:684s.
32. Hensley ML, Derosa F, Gerst SR, Sabbatini P, Dupont J, Konner J, Goss T, Orlando M, Wang Y, Aghajanian C: A phase I study of pemetrexed (P) plus gemcitabine (G) in relapsed ovarian cancer (OC): dosing results and evidence of activity (abstract 5083). Proc Am Soc Clin Oncol 2006;24:18s.
33. Peacock NW, Spigel DR, Hainsworth JD, Yardley DA, Burris HA, III, Barton JH, Patton JF, Shipley DL, Simons L, Greco FA: A phase II trial of biweekly pemetrexed (P) and gemcitabine (G) in the first-line treatment (tx) of patients (pts) with advanced non-small cell lung cancer (NSCLC) (abstract 17054). Proc Am Soc Clin Oncol 2006;24:18s.
34. Blakely J, Schnell F, Kaywin P, Keaton M, Fortner B, Epperson A, Schwartzberg LS: Phase II trial of pemetrexed (P) and gemcitabine (G) as first-line chemotherapy for elderly and/or poor performance status patients with stage IIIB/IV non-small cell lung cancer (NSCLC) (abstract 17031). Proc Am Soc Clin Oncol 2006;24:18s.
35. Dudek A, Larson, T, McCleod M, Schneider DJ, Dowell JE, Ye Z, Cunneen J, Monberg M, Tai F, Obasaju CK: Initial results of a phase II study of biweekly pemetrexed and gemcitabine in patients with advanced NSCLC (abstract 7128). Proc Am Soc Clin Oncol 2006;24:18s.